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474omalizumab], and 11.3% [placebo] for ASTERIA I; 26.8%
[75 mg of omalizumab], 42.7% [150 mg of omalizumab], 65.8%
[300 mg of omalizumab], and 19.0% [placebo] for ASTERIA II;
and 52.4% [300 mg of omalizumab] and 12.0% [placebo] for
GLACIAL) or a UAS75 0 (11.7% [75mg of omalizumab], 15.0%
[150 mg of omalizumab], 35.8% [300 mg of omalizumab], and
8.8% [placebo] for ASTERIA I; 15.9% [75 mg of omalizumab],
22.0% [150 mg of omalizumab], 44.3% [300 mg of omalizumab],
and 5.1% [placebo] for ASTERIA II; and 33.7% [300 mg of
omalizumab] and 4.8% [placebo] for GLACIAL). In patients
receiving 300 mg of omalizumab with 24 weeks of treatment,
median time to achieve a UAS7 <_ 6 was 6 weeks (ASTERIA I and
GLACIAL) and median time to achieve a UAS75 0 was 12 or
13 weeks (ASTERIA I and GLACIAL, respectively). Some
patients who achieved well-controlled urticaria or complete
response sustained response throughout the treatment period.
Conclusion: Benefits of omalizumab treatment were evident
early (before week 4) in some patients and persisted to week 24.
Use of 300 mg of omalizumab demonstrated best results in
controlling CIU/CSU symptoms. (J Allergy Clin Immunol
2016;137:474-81.)
Key words: Omalizumab, chronic idiopathic urticaria, chronic
spontaneous urticaria, responder analysis, complete response,
well-controlled urticaria
Chronic idiopathic urticaria (CIU)/chronic spontaneous
urticaria (CSU) is a condition characterized by spontaneous
appearance of pruritic hives, angioedema, or both that recur
without an identifiable external cause and persist for 6 weeks or
longer.1-3 CIU/CSU is a rare condition, and its prevalence was
reported to range between 0.6% and 0.8% in the general
population of Spain and Germany.4,5 Patients with CIU/CSU
report substantial worsening of health-related quality of life.6-8
The Urticaria Activity Score (UAS) is a validated measure to
assess disease activity in patients with CIU/CSU. The UAS score
(range, 0-6) comprises a sum of daily ratings for itch severity and
number of hives (0-3 points for each). The weekly Urticaria
Activity Score (UAS7) sums UAS scores during a 7-day period,
and possible values for the UAS7 range from 0 to 42. US and
European guidelines recommended evaluating disease activity
and response to treatment in routine clinical practice.2,3
The 2014CIU/CSUguidelines for theUnitedStates andEurope2,3
recommend treating CIU/CSU in a stepwise manner, starting with
TABLE I. Patient characteristics*
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KAPLAN ET AL 475ASTERIA I ASTERIA II GLACIALAbbreviations usedCharacteristic (n 5 318) (n 5 322) (n 5 335)CIU: Chronic idiopathic urticariaCSU: Chronic spontaneous urticaria
Age (y), mean (SD) 41.2 (14.5) 42.5 (13.7) 43.1 (14.1)LTRA: Leukotriene receptor antagonist
Female sex, no. (%) 231 (72.6) 244 (75.8) 241 (71.9)UAS: Urticaria Activity Score
Race, no. (%)UAS7: Weekly Urticaria Activity Score
White 263 (82.7) 272 (84.5) 298 (89.0)
Asian 14 (4.4) 9 (2.8) 9 (2.7)
Black 33 (10.4) 28 (8.7) 21 (6.3)
Other 8 (2.5) 13 (4.0) 7 (2.0)
Weight (kg),
mean (SD)
82.2 (21.0) 82.4 (21.9) 83.9 (22.5)
BMI (kg/m2),
mean (SD)
29.3 (6.8) 29.8 (7.3) 29.8 (7.8)
Duration of CIU (y)
Mean (SD) 6.9 (9.1) 6.5 (8.6) 7.4 (9.5)
Median (range) 3.7 (0.5-50.5) 3.3 (0.5-66.4) 3.6 (0.5-54.1)
Baseline UAS7,
mean (SD)
31.1 (6.6) 30.7 (6.8) 30.9 (6.6)
CU Index
Positive (>_10) 80 (25.2) 94 (29.3) 103 (30.9)
Negative (<10) 237 (74.8) 227 (70.7) 230 (69.1)
Total IgE level
(IU/mL)§
Mean (SD) 182.8 (387.8) 168.2 (231.9) 158.5 (287.7)
Median (range) 83 (1-5000) 78 (1-1450) 78 (1-3050)
Presence of
angioedema
at baseline (%)
151 (47.5) 131 (40.7) 178 (53.1)
BMI, Body mass index; CU, chronic urticaria.
*Individual study baseline characteristics by dose group have previously beenmonotherapy with a second-generation antihistamine.2,3 Howev-
er, complete response to H1-antihistamines has been reported to
reach slightly greater than 50% in patients with CIU/CSU.1
Although the next steps vary slightly between guidelines, recom-
mendations include increasing the dose of H1-antihistamine up to
4-fold and/or adding other therapies, such as H2-antihistamines or
leukotriene receptor antagonists (LTRAs). Should lack of control
continue, guidelines recommend using omalizumab.2,3
Data from 3 phase III clinical trials (ASTERIA I, ASTERIA II,
and GLACIAL) demonstrated the efficacy and safety of omalizu-
mab to treat patientswithCIU/CSU.9-11Despite the positive results
of these trials, many clinical questions remain regarding the
response to omalizumab in patients with CIU/CSU. The expected
timingof response toomalizumabhas not beenpreviously reported.
Furthermore, published data do not provide guidance on howmany
doses might be needed to define response or lack of response.
The aim of this analysis was to investigate response patterns of
omalizumab to treat CIU/CSU in the phase III clinical trial data,
with a goal of providing a practical approach to omalizumab use
for clinicians by using omalizumab in the real-world setting.published.9-11
ASTERIA I (n 5 313), ASTERIA II (n 5 314), pooled (n 5 627), and GLACIAL
(n 5 329).
The CU Index reflects the ability of serum to induce histamine release in normal
basophils: ASTERIA I (n 5 317), ASTERIA II (n 5 321), and GLACIAL (n 5 333).
§ASTERIA I (n 5 306), ASTERIA II (n 5 308), pooled (n 5 614), and GLACIAL
(n 5 326).METHODS
Phase III omalizumab studies
ASTERIA I,11 ASTERIA II,10 and GLACIAL9 were phase III, global,
randomized, multicenter, double-blind, placebo-controlled clinical trials
designed to assess the efficacy and safety of omalizumab use in patients
with CIU/CSU.
ASTERIA I and ASTERIA II enrolled patients with CIU/CSU who
remained symptomatic despite treatment with H1-antihistamines at approved
doses. Enrolled patients in both studies had to have a UAS7 >_ 16 (equivalent
to moderate-to-severe CIU/CSU symptoms on at least 4 of 7 days2) and an itch
component UAS7 (range, 0-21) >_ 8 for the 7 days before randomization.
Enrolled patients were randomized 1:1:1:1 to receive omalizumab (75, 150,
or 300 mg) or placebo subcutaneously every 4 weeks for 6 (ASTERIA I) or
3 (ASTERIA II) doses. In both studies, patients were observed for an addi-
tional 16 weeks without therapy. In ASTERIA I, patients were allowed to
change their background medication after week 12. The primary efficacy
end point in both studies assessed the mean change in weekly itch severity
score from baseline to week 12. The studies also evaluated the proportion of
patients who achievedwell-controlled urticaria (UAS7 <_ 6; secondary analysis
in both studies) and the proportion of patients who achieved complete
response (UAS75 0; secondary analysis in ASTERIA I and post hoc analysis
in ASTERIA II) at week 12. Additional details of the ASTERIA I and
ASTERIA II study designs have been published elsewhere.10,11
GLACIAL was a phase III, global, randomized, multicenter, double-blind,
placebo-controlled clinical trial that assessed the safety and efficacy of
omalizumab use in patients with CIU/CSU. H1-antihistamines had failed at up
to 4 times the recommended dose plus H2-antihistamines, LTRAs, or both in
GLACIAL-enrolled patients. Enrolled patients were randomized 3:1 to receive
300 mg of omalizumab or placebo subcutaneously every 4 weeks for 6 doses.
The primary end point in this study was the safety of 300 mg of omalizumab
versus placebo. The key efficacy end point included the change in the weekly
itch severity score from baseline to week 12, the proportion of patients with
well-controlled urticaria (UAS7 <_ 6) at week 12, and the proportion of patientswith complete response (UAS7 5 0) at week 12. Additional details of the
GLACIAL study design have been published by Kaplan et al.9
All 3 studies were conducted in accordance with US Food and Drug
Administration regulations, the International Conference on Harmonisation
E6 Guideline for Good Clinical Practice, and any other applicable laws.
Institutional review board approval and informed consent were obtained
from all patients. These trials are registered with ClinicalTrials.gov
(no. NCT01287117 for ASTERIA I, no. NCT01292473 for ASTERIA II,
and no. NCT01264939 for GLACIAL).
Data collection and assessments
Patients used an electronic handheld device (eDiary) to record data twice
daily for the validated Urticaria Patient Daily Diary.12-14 These data informed
the primary and many secondary end points from study patients in all 3 phase
III studies of omalizumab. The Urticaria Patient Daily Diary includes
questions about itch severity and number of hives (to assess UAS), largest
hive size, sleep interference, daily activity interference, diphenhydramine
(rescue medication use), angioedema episodes and management, and health
provider contact for CIU/CSU-related issues. Patients reported itch severity
twice daily on a scale from 0 to 3 (0, none; 1,mild; 2,moderate; and 3, severe).-
Patients also reported the number of hives twice daily on a scale from 0 to 3 (0,
none; 1, between 1 and 6 hives; 2, between 7 and 12 hives; and 3, >12 hives).
Definitions of response
The following definitions of response to treatmentwere based on theUAS7:
either complete response (itch and hive free, UAS7 5 0) or well-controlled
urticaria (UAS7 <_ 6). By design, the well-controlled urticaria group also
included complete responders.
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FIG 1. Percentage of responders by 4-week increments. A, ASTERIA I UAS7 <_ 6; B, ASTERIA I UAS7 5 0;
C, ASTERIA II UAS7 <_ 6; D, ASTERIA II UAS7 5 0; E, GLACIAL UAS7 <_ 6; and F, GLACIAL UAS7 = 0.
*P < .05 and **P < .001. OMA, Omalizumab.
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We calculated the percentage of patients who achieved responses at time
points separated by 4-week increments, as well as the percentage of non-
responders at 12 weeks who responded by week 24. We computed
the proportion of weeks in the active treatment period during which
patients experienced their responses; this analysis was performed for allpatients. We estimated the percentage of patients who achieved a response they
later sustained through the end of the drug administration period. The x2 test
was used to compare all percentages in the conducted analyses. Median time
to achieve first response was calculated using the Kaplan-Meier method; time
to achieve first response was compared between treatment groups by using
the log-rank test. All statistics were calculated with SAS 9.2 software (SAS
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FIG 2. Percentage of nonresponders at week 12 who responded by week 24 for A, well-controlled urticaria,
UAS7 <_ 6; and B, complete response, UAS7 5 0. OMA, Omalizumab.
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KAPLAN ET AL 477Institute, Cary,NC).MissingUAS7 data atweek 12 resulted in patients imputed
as nonresponders.
RESULTS
Patient demographics
In the following 3 phase III studies of omalizumab in patients
with CIU/CSU, a total of 975 patients were randomized and
received at least 1 dose of study drug: ASTERIA I (75 mg of
omalizumab [n5 77], 150mg of omalizumab [n5 80], 300mg of
omalizumab [n5 81], and placebo [n5 80]); ASTERIA II (75mg
of omalizumab [n5 82], 150mg of omalizumab [n5 82], 300mg
of omalizumab [n 5 79], and placebo [n 5 79]); and GLACIAL
(300mgof omalizumab [n5 252] and placebo [n5 83]). Baseline
patient characteristics in the studies were similar (Table I).9-11
Most of the patients in each study were white, and the majority
were female. The average age ranged from 41.2 years (ASTERIA
I) to 43.1 years (GLACIAL), and the baseline Chronic Urticaria
Index was negative (<10) for most patients (69% [GLACIAL] to
75% [ASTERIA I]). Patients’ baseline characteristic data have
been published elsewhere.9-11Responders
Response at different time points. At week 4, after a
single dose of study drug, well-controlled urticaria (UAS7 <_ 6)
was reported by 5%, 12%, 21%, and 37% of patients in ASTERIA
I (placebo and 75, 150, or 300 mg of omalizumab, respectively);
13%, 15%, 28%, and 51% of patients in ASTERIA II (placebo
and 75, 150, or 300 mg of omalizumab, respectively); and 2%
and 37% of patients in GLACIAL (placebo and 300 mg of
omalizumab, respectively). At week 4, a complete response
(UAS7 5 0) was noted in 1%, 5%, 6%, and 19% of patients in
ASTERIA I (placebo and 75, 150, or 300 mg of omalizumab,
respectively); 0%, 4%, 6%, and 24% of patients in ASTERIA II
(placebo and 75, 150, or 300 mg of omalizumab, respectively);
and 0% and 15% of patients in GLACIAL (placebo and 300mg of
omalizumab, respectively). The percentage of well-controlled
urticaria (UAS7 <_ 6) and complete responders (UAS75 0) during
the active treatment period increased with continued dosing
(Fig 1). The 300-mg dose of omalizumab produced the highest
response rates among all study arms.
Patients in ASTERIA I and GLACIAL continued to receive
therapy beyond week 12. With continued dosing, some patients
who had not met the definitions of response at week 12 met those
definitions at week 24: ASTERIA I (45.7%, 34.4%, and 58.1%,
respectively, of the 75-, 150-, and 300-mg arms and 38.2% of theplacebo arm) and GLACIAL (48.9% in the 300-mg omalizumab
arm and 14.3% in the placebo arm; Fig 2).
Median time to achieve response. Of 12 weeks of active
treatment (ASTERIA II), the median time to achieve
well-controlled urticaria (UAS7 <_ 6) was 8, 7, and 3 weeks (75,
150, and 300mg of omalizumab, respectively); fewer than 50% of
placebo patients achieved a UAS7 <_ 6 within the first 12 weeks of
active treatment, and therefore a median time to the end point
could not be calculated. In the same study, median time to achieve
complete response (UAS75 0) was 8weeks for patients receiving
300 mg of omalizumab; fewer than 50% of patients in other
treatment arms achieved a UAS75 0 within the 12-week period.
Of 24 weeks of treatment, the median time to achieve
well-controlled urticaria (UAS7 <_ 6) was 11 and 6 weeks (150 and
300 mg of omalizumab, respectively; ASTERIA I) and 6 weeks
(300mgof omalizumab,GLACIAL;Fig 3); in other treatment arms,
fewer than 50% of patients achieved the outcome by week 24. The
median time to achieve complete response (UAS7 5 0) was 12
and 13weeks (300mg of omalizumab; ASTERIA I andGLACIAL,
respectively; Fig 3); in other treatment arms fewer than 50% of pa-
tients achieved theoutcomebyweek24.Of thepatients being treated
with 300 mg of omalizumab who had not achieved well-controlled
urticaria (UAS7 <_ 6) as of week 12, 58% achieved it between weeks
13 and 24. In contrast, of the patients receiving placebowho had not
achievedwell-controlledurticaria as ofweek12, 38%achieved it be-
tween weeks 13 and 24.
Length of response. The proportion of weeks in the active
treatment (the first 12 weeks in ASTERIA II and the first 24weeks
in ASTERIA I and GLACIAL) period during which patients
experienced response was highest in the 300-mg omalizumab
treatment arm (Fig 4). To calculate this outcome, we summed the
total number of weeks during which patients reported a response
and divided it by the total number of patient-weeks in the arm.
This effect was consistent in all 3 studies.
Sustained response. Sustained response was defined as
instances when patients who achieved well-controlled urticaria
(UAS7 <_ 6) or complete response (UAS7 5 0) maintained that
response through the rest of the active treatment period (week 12
[ASTERIA II] and week 24 [ASTERIA I and GLACIAL]; Fig 5).
In the 300-mg omalizumab arms,more patients achieved sustained
responses and did so earlier than patients in other treatment arms.DISCUSSION
The results of this study illustrate the response patterns of
patients with CIU/CSU treated with omalizumab. Complete
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FIG 3. Time to achieve first well-controlled (UAS7 <_ 6) or complete (UAS75 0) response. A,ASTERIA I UAS7
<_ 6; B, ASTERIA I UAS7 5 0; C, ASTERIA II UAS7 <_ 6; D, ASTERIA II UAS7 5 0; E, GLACIAL UAS7 <_ 6; and
F, GLACIAL UAS7 5 0. OMA, Omalizumab; PBO, placebo.
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478 KAPLAN ET ALresponse (UAS7 5 0) and achievement of well-controlled
urticaria (UAS7 <_ 6) appeared early (before week 4) in some
patients, and some patients continued to achieve response up toweek 24. Some patients responded to treatment after the first
injection; however, others took longer to respond. Indeed, the fact
that some patients responded after week 12 suggests that stopping
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KAPLAN ET AL 479treatment before at least 3 omalizumab doses might miss an
opportunity to bring their CIU/CSU symptoms under control.
Overall, these results might help health care providers by setting
expectations of likelihood of response at different time points
after initiation of omalizumab.
Despite different background therapies in GLACIAL, which
allowed patients to receive higher doses of H1-antihistamines and
other background therapies (H2 blockers and LTRAs) than in
ASTERIA I and II, patients’ response patterns were comparable
among the 3 studies analogous to the similarities in efficacy
previously noted.15 All studies had patients who responded after
the first 3 doses. In all 3 studies, response manifested in a
dose-dependent manner, with the likelihood of response
increasing in patients receiving higher doses. Patients receiving
300 mg of omalizumab had a higher rate of response, and more
of them sustained their response than in other treatment arms.
Response patterns in weeks 13 to 24 were similar in ASTERIA
I and GLACIAL.
The timing of well-controlled and complete response suggests
that there might be 2 categories of responders to omalizumab:
those who respond early (before week 4) and those who require
more than 3 monthly doses to respond. The median time to
complete response was observed between 8 and 10 weeks for
300 mg of omalizumab. Early onset of omalizumab efficacy has
been reported in patients with CIU/CSU and other disease areas.
Lin et al16 followed 24 patients with adult allergic rhinitis treated
with omalizumab (0.016 mg/kg per IgE [IU/mL]) or placebo for
6 weeks. Decreases in IgE levels were reported as early as 3 days
in patients treated with omalizumab, and basophil FcεRI receptor
activity was significantly reduced by day 7 and further decreased
by day 42.16 Pereira Santos et al17 followed 2 patients with severe
uncontrolled asthma who were given 300 mg of omalizumab
every 2 weeks for 1 year; serial assessments of FcεRI expression
on basophils were performed. The reduction in FcεRI expression
was maximized mostly within the first month of treatment,
although some additional small reductions were reported during
the subsequent year of treatment. In the study by Metz et al,18
30 adults with CIU/CSUwere randomized to receive omalizumab
or placebo every 4 weeks for 12 weeks. FcεRI1 skin cell numbers
decreased in omalizumab-treated patients by day 8 and continued
to do so by day 85.18 Metz et al18 reported that among 51 patients
with chronic urticaria, 12 gained complete response within
1 week, and 6 patients did so within 4 weeks of the first
omalizumab injection. Although the early responders in our
study follow these findings, the mechanism to explain the late
responders is not completely clear.Our findings of a subpopulation of patients with CIU/CSUwith
a late response to omalizumab concur with data published by
Uysal et al.19 The authors individualized omalizumab doses and
dosing intervals to treat patients with different types of urticaria:
CIU/CSU (85%), delayed pressure urticaria (22%), urticaria
factitia (11%), contact urticaria (7%), and heat contact urticaria
(7%).19 This small single-arm open-label study included 27
patients with urticaria (aged 10-65 years) who were started on
150 mg of omalizumab. In 2 weeks, physicians evaluated each
patient’s condition and prescribed the next dose based on how
the patient responded. Approximately 56% (15/27) of patients
reached a UAS > 2 after a single 150-mg omalizumab dose and
stayed in this dose category, and the remaining patients (12/27)
received 300 mg of omalizumab at week 3 and remained in this
dose category.
In the ‘‘time to response’’ analyses, after week 12, the
Kaplan-Meier curves of the placebo and 300-mg omalizumab
groups demonstrated apparently similar slopes. By week 12,
many of the patients in the 300-mg omalizumab group had
already achieved a response (well-controlled urticaria or
complete response). Therefore, the group had begun to reach a
ceiling beyondwhich further improvement was difficult. This was
most noticeable in the patients who achieved well-controlled
urticaria (UAS7 <_ 6). However, when examining only patients
who had an opportunity for improvement, we see that the
percentage of patients who had not achieved a UAS7 <_ 6 at
week 12 but responded as such during weeks 13 to 24 was 58% in
the 300-mg omalizumab group and 38% in the placebo group.
The study was not powered to detect this end point of
improvement after 12 weeks among patients not yet achieving
response, and statistical tests comparing such end points were not
performed among this small sample; thus we are not able to draw
any strong conclusions regarding later responses to omalizumab.
Although the definitions of response were prespecified
outcomes in ASTERIA I and II and GLACIAL,9-11 the authors
are not aware of any formal definition of response to treatment
(with any medication) for patients with CIU/CSU. The state
of well-controlled urticaria (UAS7 <_ 6) is a reasonable and
clinically relevant threshold because it requires patients to be
well-controlled with onlyminimal symptoms. Complete response
(UAS7 5 0), which connotes complete elimination of itch and
hives, stands out as an attractive clinical objective but is often
difficult to achieve. Regardless of the responder definition, the
300-mg dose of omalizumab demonstrated the best outcomes.
Therefore, it might be reasonable to initiate treatment with the
300-mg dose to ensure best outcomes for the patients.
Data from this analysis might inform decisions regarding an
approach to evaluating response to omalizumab treatment.
Knowledge of expected response to omalizumab therapy might
assist prescribers in determining the length of a therapeutic trial
and inform patients or prescribers as to what to expect from
omalizumab therapy. Setting patients’ expectations regarding the
risks and benefits of a therapy can improve adherence to a
treatment regimen and contribute to optimization of outcomes.20
Continued investigation into time to response, identification of
specific phenotypes in response to omalizumab, and length of
treatment will be important to prescribers who have patients who
require omalizumab formanagement of CIU/CSU. Improving our
understanding of the activity of omalizumab in the inflammatory
process associated with symptomatic CIU/CSU and recognizing
that a subset of patients might have a delay in response could also
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480 KAPLAN ET ALhelp to inform decisions regarding optimization of omalizumab
therapy.
Although phase III, randomized, double-blind, placebo-
controlled trials remain the gold standard for establishing efficacy,the results of this analysis should be interpreted in light of its
limitations. Clinical trial data were not available beyond week 24,
and therefore information on the response to treatment beyond this
time is unknown. Results from a phase II dose-ranging study
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KAPLAN ET AL 481provided the framework for the flat dosing (non-IgE and
non–weight-based dosing) and 4-week interval used in the pivotal
studies.21 Despite evidence from the phase II and 3 phase III
proof-of-concept studies,9-11 it must be acknowledged that we still
have much to learn about optimal dosing of omalizumab in
patients with CIU/CSU. On the basis of Genentech’s data on
file, we also know that the patients in the placebo arm used
more background therapy than patients in the omalizumab arm.
Therefore, such misbalance is likely to have unfavorably
affected omalizumab arms, as opposed to the placebo arm. In
addition, these studies permitted the use of rescue medication
(diphenhydramine), and our analysis did not control for rescue
medication use. Finally, the comparison arm of these studies
included placebo plus standard of care and thus was not a pure
untreated placebo arm.
Although this study highlighted 2 categories of responders
(ie, early and late) the exact mechanisms responsible for these
responses are not completely clear. In addition, some patients
experienced relapse of their symptoms during either the treatment
or follow-up periods. Understanding patterns in relapses might
help physicians effectively dose omalizumab in their practice,
although relapse analysis was outside the scope of this study.
Further research is needed to understand characteristics
predictive of early versus late response, as well as relapse patterns
in patients with CIU/CSU treated with omalizumab.
In summary, response patterns to treatment of CIU/CSU with
omalizumab were dose dependent; use of the 300-mg dose of
omalizumab resulted in the largest percentage of patients who
achieved a complete response (UAS7 5 0) or well-controlled
urticaria (UAS7 <_ 6). Half of the patients treated with 300 mg of
omalizumab had well-controlled symptoms after 2 injections
(median time to response, 6 weeks). The benefits of omalizumab
treatment in patients with CIU/CSU were evident to week 24.
These data highlight the likelihood of response to omalizumab in
patients with CIU/CSU at different time points and will help
prescribers set patients’ expectations for therapy.
We thank the clinical trial investigators, staff, and patients who participated
in the studies. Medical writing support was provided by Linda Wagner,
PharmD, of Excel Scientific Solutions and funded by Genentech, Inc and
Novartis Pharmaceuticals Corporation.
Clinical implications: In patients with CIU/CSU, response to
omalizumab was dose dependent; treatment with 300 mg of
omalizumab resulted in earlier response (before week 4), and
response was sustained to week 24.
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